Dmitriy Niyazov, MD
Clinical Genetics (M.D.) · Durham, NCNPI 1699950899
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $270,764 of the $330,924 with a category attached, or 81.8%. Sanofi accounts for 60.3% of it on its own, with 10 other manufacturers making up the rest.
Across 434 payments — averaging $762.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$200K
- AstraZeneca$116K
- Sarepta Therapeutics, Inc.$7K
- Amicus Therapeutics, Inc.$4K
- Zevra Therapeutics Inc$2K
- Biomarin Pharmaceutical Inc.$1K
- plus $785 from 5 others
What the payments were for
- Consulting fees$14,7994%
- Speaking & faculty fees$270,76482%
- Travel & lodging$38,13812%
- Food & beverage$7,2092%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 218 | $199,590 |
| AstraZeneca | 195 | $116,184 |
| Sarepta Therapeutics, Inc. | 9 | $6,847 |
| Amicus Therapeutics, Inc. | 3 | $4,469 |
| Zevra Therapeutics Inc | 1 | $1,680 |
| Biomarin Pharmaceutical Inc. | 1 | $1,369 |
| Sanofi-aventis U.S. LLC | 2 | $393 |
| Chiesi USA, Inc. | 1 | $300 |
| Jazz Pharmaceuticals Inc. | 2 | $45 |
| Travere Therapeutics, Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXVIAZYME$78,012
- CERDELGA$52,719
- CEREZYME$52,419
- Strensiq$33,053
- FABRAZYME$32,952
- LUMIZYME$23,142
- ALDURAZYME$2,289
- Olpruva$1,680
- NO PRODUCT DISCUSSED$1,376
- ELFABRIO$300
How this compares
Too few clinical genetics (m.d.) providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other clinical genetics (m.d.) in Durham
- Areeg El-GharbawyDurham$5K
- Vandana ShashiDurham$17
- Susan SparksCharlotte$17K
- Chad Haldeman EnglertGreensboro$12K
- Rose GuoGreensboro$618
- Laurie DemmerCharlotte$117
- Lauren CarterCharlotte$50
- Karen SchmidtGreenville$12
- Margie JaworskiGreenville$12
- Tamison JewettWinston Salem$2
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.